Latest Ratios: P/E Ratio -2.3x · EV/EBITDA N/A · ROE -134.4%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $94M | $91M | $51M | $83M | $185M | $114M | $209M | $83M | $173M | — | — |
| Enterprise Value | $150M | $147M | $114M | $86M | $154M | $59M | $199M | $41M | $99M | — | — |
| P/E Ratio → | -2.29 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.63 | 0.61 | 0.68 | 1.16 | 2.83 | 2.05 | 4.25 | 1.32 | 3.28 | — | — |
| P/B Ratio | 3.39 | 3.47 | 1.61 | 2.43 | 3.24 | 1.33 | 8.21 | 1.72 | 2.44 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.99 | 1.53 | 1.20 | 2.36 | 1.07 | 4.03 | 0.66 | 1.88 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 48.5% | 48.5% | 72.3% | 72.5% | 76.3% | 78.9% | 76.5% | 75.4% | 76.4% | 76.2% | 80.7% |
| Operating Margin | -21.1% | -21.1% | -46.2% | -42.8% | -53.8% | -49.8% | -45.3% | -43.0% | -37.6% | -33.7% | -27.3% |
| Net Profit Margin | -26.1% | -26.1% | -58.4% | -42.3% | -57.0% | -56.4% | -55.7% | -46.4% | -45.7% | -39.7% | -32.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -134.4% | -134.4% | -132.5% | -66.2% | -52.3% | -56.4% | -74.9% | -48.9% | -33.9% | — | — |
| ROA | -27.6% | -27.6% | -34.0% | -25.9% | -28.8% | -28.4% | -30.7% | -26.7% | -30.9% | -50.4% | -45.3% |
| ROIC | -26.6% | -26.6% | -39.3% | -72.2% | -92.3% | -91.0% | -156.8% | -1215.3% | — | — | — |
| ROCE | -28.5% | -28.5% | -33.6% | -34.0% | -33.6% | -28.9% | -32.5% | -30.6% | -30.4% | -70.9% | -81.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.44 | 3.44 | 2.60 | 1.83 | 0.70 | 0.46 | 1.50 | 0.72 | 0.43 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 2.14 | 1.99 | 0.08 | -0.54 | -0.64 | -0.42 | -0.86 | -1.04 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.74 | -3.74 | -5.00 | -4.57 | -9.34 | -8.45 | -5.93 | -7.67 | -5.53 | -4.72 | -5.12 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.02 | 2.02 | 1.86 | 4.73 | 2.98 | 7.34 | 4.75 | 3.19 | 8.44 | 3.09 | 1.72 |
| Quick Ratio | 1.87 | 1.87 | 1.72 | 4.33 | 2.71 | 6.93 | 4.48 | 3.09 | 8.26 | 2.88 | 1.59 |
| Cash Ratio | 1.13 | 1.13 | 0.63 | 3.06 | 2.17 | 6.14 | 3.72 | 2.77 | 7.71 | 2.43 | 1.28 |
| Asset Turnover | — | 1.05 | 0.53 | 0.62 | 0.56 | 0.39 | 0.63 | 0.63 | 0.45 | 1.04 | 1.38 |
| Inventory Turnover | 17.76 | 17.76 | 4.88 | 2.43 | 1.74 | 1.78 | 3.11 | 5.55 | 5.12 | 3.90 | 3.90 |
| Days Sales Outstanding | — | 41.34 | 118.36 | 91.26 | 77.36 | 51.34 | 53.11 | 38.27 | 38.87 | 38.52 | 38.14 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $66M | $32M | $29M | $27M | $25M | $19M | $18M | $9M | $11220 | $11220 |
Liquidity and solvency pressure
Based on current market data, STIM trades at a P/S ratio of 0.63, which, when viewed alongside a negative P/E of -2.27, suggests that investors are heavily discounting the company's future growth potential due to persistent operational losses and significant uncertainty regarding the path to sustainable profitability.
The low P/S multiple relative to broader med-tech peers indicates that the market is pricing the company as a distressed asset rather than a growth-stage medical device firm. This valuation suggests that the market remains skeptical of management's ability to convert its installed base into meaningful bottom-line earnings.
As reported in recent financial statements, the company's ROIC has consistently languished in negative territory, reaching -12.2% in 2026Q1, which highlights a fundamental inability to generate returns on invested capital that exceed the cost of funding the firm's aggressive commercial expansion and infrastructure development.
The persistent decay in ROIC suggests that each dollar of capital deployed into the business is currently destroying shareholder value rather than compounding it. This trend warrants further investigation into whether the company's high-cost sales model is structurally incompatible with the current market size for TMS therapy.
According to quarterly filings, the cash conversion cycle has fluctuated wildly, dropping from 182 days in 2023Q4 to 11 days in 2026Q1, which indicates significant instability in managing receivables and inventory levels as the company attempts to scale its hardware placement and consumable revenue streams simultaneously.
The extreme volatility in the cash conversion cycle suggests that the company lacks a mature operational rhythm, potentially exposing it to liquidity shocks during periods of slower system sales. Investors should monitor whether the recent compression in the cycle is a sustainable efficiency gain or merely a temporary byproduct of aggressive inventory liquidation.
Based on reported figures, the debt-to-equity ratio has surged to 1.41 in 2026Q1, reflecting a precarious reliance on external financing to sustain operations as the equity base continues to erode under the weight of ongoing net losses and the accumulation of intangible assets like goodwill.
The rising leverage profile, coupled with negative interest coverage, suggests that the company's ability to service its debt is becoming increasingly strained. This trajectory implies that management may face limited options for future financing without further diluting existing shareholders or accepting restrictive debt covenants.
The most commonly misapplied metric for this business is top-line revenue growth, which frequently obscures the underlying cash burn and the lack of operating leverage inherent in the company's current high-cost, direct-sales-driven model for placing medical hardware into psychiatric practices.
Analysts often focus on revenue expansion as a proxy for market penetration, but this ignores the fact that the cost of acquiring each new system placement currently exceeds the lifetime value of the associated recurring revenue. A more appropriate metric would be the contribution margin per installed system, which would better reveal the true economic viability of the company's razor-and-blade business model.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying STIM stock.
Neuronetics, Inc.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
Neuronetics, Inc.'s return on equity (ROE) is -134.4%. The historical average is -74.9%.
Based on historical data, Neuronetics, Inc. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Neuronetics, Inc. has 48.5% gross margin and -21.1% operating margin.